Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Earnings Data
Report Date
May 11, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.9Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlighted strong commercial momentum across core franchises with notable volume growth (105K total test reports, +37%; TissueCypher +86%) and promising early uptake of new products (AdvanceAD-Tx ~500 orders in initial period). The company has a healthy cash balance (~$299.5M) and generated positive free cash flow in 2025. However, profitability and margin metrics deteriorated materially year-over-year (full year net loss $24.2M, adjusted EBITDA down to $44M from $75M, gross margin compressed to 69.2%), driven by lost DecisionDx-SCC revenue, a one-time amortization charge and higher operating expenses. Additional near-term risks include guideline and reimbursement uncertainties and timing for FDA clearance and reimbursement for new tests. Overall the operational growth story and cash strength balance against weakened profitability and reimbursement/timing risks.Company Guidance
Full Year and Q4 Revenue Beat
Q4 2025 revenue of $87.0M and full year 2025 revenue of $344.2M, which exceeded guidance.
Strong Overall Test Volume Growth
Total test report volume of 105,053 for 2025, up 37% year-over-year versus 2024.
TissueCypher Rapid Adoption
TissueCypher delivered 39,014 test reports in 2025 vs 20,956 in 2024, representing 86% growth; surpassed ~80,000 tests ordered to date; 2,082 new ordering clinicians in 2025 (up from 1,234 in 2024, ~69% increase); patient penetration ~11% exiting 2025.
DecisionDx-Melanoma Continued Momentum and Evidence Base
DecisionDx-Melanoma delivered 39,083 test reports in 2025, +9% year-over-year; 1,795 clinicians ordered for the first time in 2025; lifetime ordering clinicians nearing 17,000; ~58 peer-reviewed publications supporting clinical use; patient penetration ~31% exiting 2025.
AdvanceAD-Tx Early Launch Success
AdvanceAD-Tx launched on limited access late Nov 2025 to ~150 dermatology accounts; over half of initial accounts ordered within first five weeks and ~500 orders through mid-February; company expects immaterial revenue in 2026 and material contribution in 2027–2028.
Strategic M&A and Pipeline Progress
Acquisition of Previse (non-endoscopic cell collection device) with plan to start development study enrollment in Q2 2026 and expect preliminary data before end of 2026; collaboration with SciBase to initiate EIS PEN study for AD flares in Q2 2026 with preliminary data expected before year-end; company reiterates M&A as a growth tool with clear criteria.
Solid Cash Position and Positive Free Cash Flow
Cash, cash equivalents and marketable securities of $299.5M as of Dec 31, 2025; generated free cash flow of $28.3M in 2025 (net cash provided by operations $64.3M less capex $36M); net cash provided by operations in Q4 was $26.9M.
Guidance Reflects Adjusted Growth Expectation
2026 revenue guidance of $340M–$350M; company states this equates to mid- to high-teens growth over 2025 when excluding DecisionDx-SCC and IDgenetix revenue from both years, signaling management expects continued core-franchise growth.
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $31.88 | ― | ― |
Nov 03, 2025 | $25.99 | $31.63 | +21.70% |
Aug 04, 2025 | $15.32 | $20.35 | +32.83% |
May 05, 2025 | $18.75 | $16.62 | -11.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on May 11, 2026, After Close (Confirmed).
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at May 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2026 (Q1) is -0.51.